Pranlukast is a drug in the BCS class II category, and its absolute bioavailability is around 4.3%. PEG 4000 and PEG 6000 were used in the development of the pranlukast solid dispersion with oral disintegrating tablet to boost the drug's biological performance. Multiple carriers were used to create solid dispersions of pranlukast (1:0.25, and 1:0.5). Solvent evaporation prepared Pranlukast solid dispersions were discussed in relation to studies examining their solubility, melting point, drug content uniformity, entrapment efficiency, and in vitro dissolution. The solid state was characterised using a variety of analytical techniques, including FT-IR studies. Following a thorough analysis of all four formulations (SF1-SF4), it was concluded that formulation(SF4) containing Pranlukast+ PEG 6000 (1:0.5) showed the best results by solvent evaporation method at the end of 90 min with drug release of 82.96 percent. Changes in disintegrant concentration allowed the optimised formulation to be used to create immediate release tablets. Prior to and following compression, extensive analysis was performed on theinput parameters. These results are all within a reasonable margin of error. The effectiveness of the tablets' drug delivery was evaluated in a laboratory dish using a buffer with a pH of 6.8. Cross caramellose sodium (7.5mg) is used in Formulation F6, and it results in a 98.02 percent drug release in 40 minutes. Zero order release kinetics is essential for the best formulation